The post hoc analysis of phase 2 of the tirzepatide trial showed that a higher dose of this novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist could significantly decrease the level of NASH-related biomarkers and increase adiponectin level in patients with T2D [23]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.